Palbociclib (PD0332991)—a Selective and Potent Cyclin-Dependent Kinase Inhibitor-Reference-Cited by-同舟云学术

Palbociclib (PD0332991)—a Selective and Potent Cyclin-Dependent Kinase Inhibitor

Published:2016-02-01 Issue:2 Volume:2 Page:253
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Clark Amy S.¹,Karasic Thomas B.²,DeMichele Angela³,Vaughn David J.¹,O’Hara Mark¹,Perini Rodolfo⁴,Zhang Paul⁵,Lal Priti⁵,Feldman Michael⁵,Gallagher Maryann⁶,O’Dwyer Peter J.¹

Affiliation:

1. Abramson Cancer Center, Philadelphia, Pennsylvania2Division of Hematology/Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia

2. Division of Hematology/Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia

3. Abramson Cancer Center, Philadelphia, Pennsylvania2Division of Hematology/Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia3Center for Clinical Epidemiology and Biostatistics, Philadelphia, Pennsylvania4Division of Nucl

4. Abramson Cancer Center, Philadelphia, Pennsylvania4Division of Nuclear Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia

5. Department of Pathology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia

6. Abramson Cancer Center, Philadelphia, Pennsylvania

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral nano-formulations for endocrine therapy of endometrioid adenocarcinomas;Biomedicine & Pharmacotherapy;2024-10

2. Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity;European Journal of Medicinal Chemistry;2024-09

3. Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer;The Breast;2024-08

4. Monoallelic KRAS (G13C) mutation triggers dysregulated expansion in induced pluripotent stem cell-derived hematopoietic progenitor cells;Stem Cell Research & Therapy;2024-04-16

5. Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion;Experimental Hematology & Oncology;2024-03-25